ANNX vs RZLT
ANNX: Annexon is a clinical-stage biotechnology company developing C1q-inhibitor therapies to treat neurodegenerative and autoimmune diseases driven by the classical complement pathway. RZLT: Rezolute is a clinical-stage biopharmaceutical company developing targeted therapeutic solutions for rare and chronic metabolic and endocrine diseases.
Side-by-side fundamentals
| Metric | ANNX | RZLT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.23 | $5.00 | |
| Market cap as of 2026-07-23 | $857M | $481M | |
| PEG as of 2026-07-23 | -1.19 | n/a | |
| ROE as of 2026-07-23 | -101.2% | -58.8% | RZLT higher |
| ROA as of 2026-07-23 | -76.0% | -54.5% | RZLT higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-23 | 1.18 | 0.58 | |
| 1-year return as of 2026-07-22 close | +118.2% | -6.9% | ANNX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.